Skip to main content
. 2017 Dec 28;17:216. doi: 10.1186/s12890-017-0563-7

Table 5.

Summary of AEs in switched patients during the washout phase of the study

AE, n (%) Switched patients
(n = 84)a
Any AE 11 (13)
Maximum intensity of any AE
 Mild 8 (10)
 Moderate 3 (4)
Any serious AE 2 (2)
Deaths 0 (0)

AE adverse event, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5

aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat